"The new Avellino Dual Test is easy and safe," says Dr. Tom Tooma, founder of NVISION Laser Eye Centers.
Newport Beach, California (PRWEB) April 27, 2014
NVISION Laser Eye Centers today announced an agreement with Avellino Labs USA to be the first in the nation to offer a new genetic test that can detect both the Avellino Corneal Dystrophy (ACD) gene as well as another genetic mutation, Granular Corneal Dystrophy type 1 (GCD1).
GCD1 and ACD, also known as GCD2, are characterized by small translucent dots, or granules, resembling crushed bread crumbs that form in the various layers of the cornea. Similar to GCD2, GCD1 typically develops slowly. However, should a patient with GCD1 undergo vision correction surgery (e.g. LASIK, LASEK, PRK), he or she is at extreme risk of experiencing eventual blindness if they have the genetic mutation.
With the Avellino DNA Dual Test, a patient can now simultaneously determine if he or she has GCD1 or GCD2 prior to undergoing LASIK, avoiding the risk of post-surgery vision complications.
“The Avellino DNA Test for LASIK Safety has been a vital tool for our physicians to have access to in order to ensure the safety of our patients,” said Dr. Tom Tooma, founder of NVISION Laser Eye Centers. “We’re excited to offer our physicians and patients the new Avellino DNA Dual Test. Our patients can now go into LASIK treatment with the confidence they are protected against unwanted outcomes.”
“The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries either of these genetic mutations. Within 24 to 48 hours, the results are provided to our doctors to share with our patients,” concludes Tooma.
“NVISION Laser Eye Centers has been a valuable customer to our company since the launch last year,” said Avellino Lab USA COO Scott Korney. “Having NVISION offer the latest Avellino DNA Test for LASIK Safety demonstrates their commitment to providing its patients with the most innovative care.”
About NVISION Laser Eye Centers
NVISION Laser Eye Centers is an innovative leader in lifestyle surgical eye care with 17 locations in California and Nevada. NVISION is the first provider in California to offer LASIK eye surgery with the Swiss-engineered Ziemer Femto LDV™ Crystal Line Laser. In addition, NVISION is the first provider in California to offer the bladeless, computer-controlled LenSx® laser -- unquestionably the most technologically advanced option for laser cataract surgery -- and the first in the nation to offer Avellino DNA testing for an added level of LASIK safety.
With more than 1500 eye doctors who refer their patients and trust their own eyes to NVISION surgeons, NVISION Laser Eye Centers is the Eye Doctors’ #1 Choice®. For more information, visit http://www.NVISIONCenters.com or call 1-877-91NVISION (1-877-916-8474).
About Avellino Lab USA
Avellino Lab USA has developed the first and only commercially available testing system, the Avellino DNA Dual Test for LASIK Safety, for Granular Corneal Dystrophy type 1 (GCD1) and Granular Corneal Dystrophy type 2 (GCD2), also known as Avellino Corneal Dystrophy (ACD). The company’s proprietary genetic diagnostics system provides fast, safe and affordable evaluations of an individual’s genetic predisposition to GCD1 and/or GCD2. With the Avellino DNA Dual Test, Avellino Lab USA is able to positively identify, with high accuracy, a patient’s GCD status. Based on the test’s results, patients and their physician can make an informed decision when considering vision correction surgery.